The presence of NPM1 mutation in AML stem/progenitor cells (LSCs) has been documented to be associated with but not shown to be causally linked to increased sensitivity to AML therapies, including treatment with menin inhibitor, the exportin-1 inhibitor selinexor, RARA or RXR agonists, or with the chemotherapeutic agents cytarabine and daunorubicin. This evidence concerns the gene XPO1 and acute myeloid leukemia.